IKNA

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $-413.9K ExitQ3 2025 $414k -- --
Ken GriffinCitadel Advisors $-212.0K ExitQ3 2025 $212k -- --
Ken GriffinCitadel Advisors $110.0K AddQ2 2025 $110k -- --
Jim SimonsRenaissance Technologies $36.9K AddQ2 2025 $37k -- --
Jim SimonsRenaissance Technologies $-164.6K TrimQ1 2025 $165k -- --
Ken GriffinCitadel Advisors $-29.8K TrimQ1 2025 $30k -- --

Trade IKNA

About Ikena Oncology, Inc.

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.

CEO: Mark Manfredi
IPO Date: Mar 26, 2021

Market Data

Open: $1.38
High: $17.16
Low: $1.36
Volume: 457.3K
52W High: $23.28
52W Low: $1.36

Valuation

Market Cap: $719M
Enterprise Value: $-5.3M

Financials

Free Cash Flow: $-48M
Revenue: $0
Net Income: $-52M
Cash: $35M
Debt: $0

Events

EarningsMar 4